Literature DB >> 15899223

[Neuroblastoma].

Victoria Castel1, Adela Cañete, Rosa Noguera, Samuel Navarro, Silvestre Oltra.   

Abstract

Entities:  

Mesh：

Year:  2005        PMID： 15899223     DOI： 10.1007/bf02708748

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN： 1699-048X            Impact factor:   3.405


× No keyword cloud information.
  81 in total

1.  Successful treatment of stage III neuroblastoma based on prospective biologic staging: a Children's Cancer Group study.

Authors:  K K Matthay; C Perez; R C Seeger; G M Brodeur; H Shimada; J B Atkinson; C T Black; R Gerbing; G M Haase; D O Stram; P Swift; J N Lukens
Journal:  J Clin Oncol       Date:  1998-04       Impact factor: 44.544

2.  OPEC/OJEC for stage 4 neuroblastoma in children over 1 year of age.

Authors:  D A Tweddle; C R Pinkerton; I J Lewis; C Ellershaw; M Cole; A D Pearson
Journal:  Med Pediatr Oncol       Date:  2001-01

3.  A population-based study of the usefulness of screening for neuroblastoma.

Authors:  W G Woods; M Tuchman; L L Robison; M Bernstein; J M Leclerc; L C Brisson; J Brossard; G Hill; J Shuster; R Luepker; T Byrne; S Weitzman; G Bunin; B Lemieux
Journal:  Lancet       Date:  1996 Dec 21-28       Impact factor: 79.321

4.  Allogeneic versus autologous purged bone marrow transplantation for neuroblastoma: a report from the Childrens Cancer Group.

Authors:  K K Matthay; R C Seeger; C P Reynolds; D O Stram; M C O'Leary; R E Harris; M Selch; J B Atkinson; G M Haase; N K Ramsay
Journal:  J Clin Oncol       Date:  1994-11       Impact factor: 44.544

5.  Prognostic significance of age, MYCN oncogene amplification, tumor cell ploidy, and histology in 110 infants with stage D(S) neuroblastoma: the pediatric oncology group experience--a pediatric oncology group study.

Authors:  H M Katzenstein; L C Bowman; G M Brodeur; P S Thorner; V V Joshi; E I Smith; A T Look; S T Rowe; M B Nash; T Holbrook; C Alvarado; P V Rao; R P Castleberry; S L Cohn
Journal:  J Clin Oncol       Date:  1998-06       Impact factor: 44.544

Review 6.  Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment.

Authors:  G M Brodeur; J Pritchard; F Berthold; N L Carlsen; V Castel; R P Castelberry; B De Bernardi; A E Evans; M Favrot; F Hedborg
Journal:  J Clin Oncol       Date:  1993-08       Impact factor: 44.544

7.  Significance of molecular quantification of minimal residual disease in metastatic neuroblastoma.

Authors:  Andrei Tchirkov; Catherine Paillard; Pascale Halle; Frédéric Bernard; Pierre Bordigoni; Philippe Vago; François Deméocq; Justyna Kanold
Journal:  J Hematother Stem Cell Res       Date:  2003-08

8.  FISH analyses for alterations in chromosomes 1, 2, 3, and 11 define high-risk groups in neuroblastoma.

Authors:  Ruediger Spitz; Barbara Hero; Karen Ernestus; Frank Berthold
Journal:  Med Pediatr Oncol       Date:  2003-07

9.  Co-amplification of MYCN and a DEAD box gene (DDX1) in primary neuroblastoma.

Authors:  J A Squire; P S Thorner; S Weitzman; J D Maggi; P Dirks; J Doyle; M Hale; R Godbout
Journal:  Oncogene       Date:  1995-04-06       Impact factor: 9.867

10.  High dose melphalan in the treatment of advanced neuroblastoma: results of a randomised trial (ENSG-1) by the European Neuroblastoma Study Group.

Authors:  Jon Pritchard; Simon J Cotterill; Shirley M Germond; John Imeson; Jan de Kraker; David R Jones
Journal:  Pediatr Blood Cancer       Date:  2005-04       Impact factor: 3.167
View more
  1 in total

1.  Neuroblastoma in adolescents: genetic and clinical characterisation.

Authors:  Victoria Castel; Eva Villamón; Adela Cañete; Samuel Navarro; Amparo Ruiz; Carmen Melero; Antonio Herrero; Yania Yáñez; Rosa Noguera
Journal:  Clin Transl Oncol       Date:  2010-01       Impact factor: 3.405
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.